PNC Financial Services Group
PLX icon

PNC Financial Services Group’s Protalix BioTherapeutics PLX Stock Holding History

PNC Financial Services Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43 Hold
20
– – ﹤0.01% 5133
2025
Q4 		$36 Sell
20
-15
-43% -$31 ﹤0.01% 5112
2025
Q3 		$78 Buy
+35
New +$57 ﹤0.01% 5013
2024
Q3 		– Sell
-1,418
Closed -$1.66K – 4885
2024
Q2 		$1.66K Buy
+1,418
New +$1.68K ﹤0.01% 4301
2024
Q1 		– Sell
-19
Closed -$34 – 4788
2023
Q4 		$34 Buy
+19
New +$30 ﹤0.01% 4585

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

PNC Financial Services Group's PLX Position: Q1 2026 in Review

PNC Financial Services Group held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 20 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #5133.

PNC Financial Services Group first reported a position in PLX in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.66K in Q2 2024. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • PNC Financial Services Group held 20 shares of Protalix BioTherapeutics worth $43 as of Q1 2026.
  • PNC Financial Services Group left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5133 holding.
  • PNC Financial Services Group first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 5 quarters since.
  • PNC Financial Services Group's Protalix BioTherapeutics position peaked at $1.66K in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.